Chromosome anomalies in mouse zygotes treated by growth hormone-releasing factor.
The incidence of chromosome anomalies was studied in fertilized oocytes in two groups of hybrid mice in which superovulation was induced by gonadotrophins and growth hormone-releasing factor (GRF) supplementation or gonadotrophins alone (controls). The rate of fertilization was significantly higher among GRF-treated females than among controls (74.1 versus 84.7%; P < 0.013). Cytogenetic data were obtained in 262 fertilized oocytes (89 from control females and 173 from GRF-treated females). The frequency of aneuploidy, calculated as twice the frequency of hyperhaploidy was 2.31% in GRF-treated females and 2.24% in controls (NS). The use of GRF to treat female mice did not adversely affect the maturation process of oocytes nor did it induce an increased frequency of aneuploidy.
Arán
B
B
Departament d'Obstetricia i Ginecologia, Institut Universitari Dexeus, Barcelona, Spain.
Calderón
G
G
Moragas
M
M
Torelló
M J
MJ
Veiga
A
A
Barri
P N
PN
D000818:Animals; D002869:Chromosome Aberrations; D002875:Chromosomes / Q000187:drug effects*; D005260:Female; D006064:Gonadotropins, Equine / Q000627:therapeutic use; D013007:Growth Hormone-Releasing Hormone / Q000494:pharmacology* / Q000627:therapeutic use; D008431:Maternal-Fetal Exchange; D051379:Mice; D010062:Ovulation Induction / Q000379:methods; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D013480:Superovulation; D015053:Zygote / Q000187:drug effects*
D006064:Gonadotropins, Equine; D013007:Growth Hormone-Releasing Hormone